Comparative Pharmacology
Head-to-head clinical analysis: BRIXADI versus PROBUPHINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIXADI versus PROBUPHINE.
BRIXADI vs PROBUPHINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.
Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.
Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.
None Documented
None Documented
Terminal half-life approximately 470–500 hours (~20 days) following intramuscular injection, allowing weekly or monthly dosing.
Terminal elimination half-life: 37 hours (range 24-48 h) due to slow release from tissue binding and enterohepatic recirculation; contributes to prolonged dosing interval (every 4 weeks) and delayed withdrawal onset.
Primarily fecal (80–90%) as unchanged drug; renal elimination accounts for <5% of the dose.
Primarily renal (70-80% as unchanged drug and active metabolite norbuprenorphine), biliary/fecal (20-30%)
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist